icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
bWa2kxeuCLxv9Y4p
Listen
